Table 2.
Zero-Order Correlations Between HiTOP Measures, Diagnoses, and Outcome Measures
| 1. | 2. | 3. | 4. | 5. | 6. | 7. | 8. | 9. | 10. | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1. SAPS Reality Distortion | ||||||||||
| 2. SAPS Disorganization | 0.45*** | |||||||||
| 3. SANS Avolition | 0.25*** | 0.26*** | ||||||||
| 4. SANS Inexpressivity | 0.18** | 0.17** | 0.52*** | |||||||
| 5. QLS Global Functioning | −0.37*** | −0.29*** | −0.72*** | −0.49*** | ||||||
| 6. Schizophrenia | 0.27*** | 0.13* | 0.27*** | 0.38*** | −0.29*** | |||||
| 7. BD-P | −0.20*** | −0.02 | −0.26*** | −0.29*** | 0.32*** | −0.46*** | ||||
| 8. MDD-P | −0.09 | −0.13* | −0.05 | −0.10 | 0.03 | −0.35*** | −0.30*** | |||
| 9. SI psychosis | −0.01 | −0.05 | 0.02 | −0.01 | 0.01 | −0.20*** | −0.17** | −0.13* | ||
| 10. Other psychoses | −0.01 | 0.02 | 0.01 | −0.02 | −0.06 | −0.27*** | −0.23*** | −0.17** | -0.10 | |
| 11. Recovery | −0.23*** | −0.18** | −0.43*** | −0.26*** | 0.42*** | −0.27*** | 0.27*** | 0.09 | −0.09 | −0.02 |
| 12. Full symptom remission | −0.15* | −0.17** | −0.34*** | −0.38*** | 0.35*** | −0.37*** | 0.28*** | 0.20** | −0.07 | −0.01 |
| 13. Educational attainment | −0.10 | −0.08 | −0.24*** | −0.18** | 0.26*** | −0.05 | 0.19** | −0.04 | −0.07 | −0.09 |
| 14. Employed | −0.21*** | −0.15** | −0.30*** | −0.26*** | 0.34*** | −0.16** | 0.25*** | −0.05 | −0.01 | −0.03 |
| 15. Public assistance | 0.22*** | 0.15** | 0.33*** | 0.31*** | −0.37*** | 0.26*** | −0.25*** | −0.04 | −0.02 | 0.03 |
| 16. Role functioning | −0.22*** | −0.19** | −0.43*** | −0.32*** | 0.42*** | −0.26*** | 0.25*** | 0.14* | −0.05 | −0.08 |
| 17. Living independently | −0.18** | −0.12* | −0.20*** | −0.27*** | 0.28*** | −0.30*** | 0.20*** | 0.13* | 0.00 | 0.00 |
| 18. Social functioning | −0.14* | −0.17** | −0.47*** | −0.30*** | 0.41*** | −0.17** | 0.21*** | 0.06 | −0.08 | −0.06 |
| 19. WHO-DAS Global Disability | 0.21** | 0.15* | 0.37*** | 0.15* | −0.30*** | 0.08 | −0.24*** | 0.11 | 0.13* | 0.00 |
| 20. Diabetes | 0.14* | 0.06 | 0.23*** | 0.10** | −0.20*** | 0.11** | −0.16** | 0.01 | 0.05 | 0.00 |
| 21. Hypertension | 0.13* | 0.14* | 0.10 | 0.05 | −0.08 | 0.01 | −0.02 | 0.08 | −0.05 | −0.05 |
| 22. MMN duration | 0.21** | 0.12 | 0.15* | 0.15* | −0.11 | 0.13** | −0.03 | −0.01 | −0.01 | −0.14** |
| 23. MMN frequency | 0.04 | −0.04 | 0.01 | 0.10 | −0.02 | 0.00 | 0.01 | −0.01 | 0.06 | −0.05 |
| 24. P3a amplitude | −0.02 | −0.04 | −0.14** | 0.01 | 0.21** | −0.06 | −0.01 | 0.09 | 0.00 | 0.01 |
| 25. P3a latency | 0.03 | 0.04 | 0.14* | −0.04 | −0.01 | −0.09 | 0.08 | 0.06 | −0.08 | 0.02 |
| 26. Cognition composite | −0.19* | −0.15* | −0.24** | −0.34*** | 0.29*** | −0.23** | 0.37*** | −0.06 | 0.08 | −0.17* |
Note: SAPS, Scale for the Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative Symptoms; QLS, Quality of Life Scale; BD-P, Bipolar disorder with psychotic features; MDD-P, Major depressive disorder with psychotic features; SI psychosis, Substance-induced psychosis; WHO-DAS, World Health Organization Disability Assessment Schedule; MMN, Mismatched negativity.
*P < .05, **P < .01, *** P< .001.